Maryland-based biopharmaceutical company MacroGenics, Inc. is making strides in the fight against cancer with its line of antibody-based therapeutics. The company's flagship product, MARGENZA, has been approved for the treatment of metastatic HER2-positive breast cancer in combination with chemotherapy. MacroGenics also has a promising pipeline of immuno-oncology product candidates, including Enoblituzumab, MGC018, and MGD024, which target solid tumors expressing B7-H3. In addition, MacroGenics is working on Lorigerlimab, Tebotelimab, Retifanlimab, and IMGC936, all of which target various aspects of the immune system to improve cancer therapeutics. The company has also developed Teplizumab for the treatment of type 1 diabetes and PRV-3279 for the treatment of autoimmune disorders. MacroGenics has collaborations in place with companies including Incyte Corporation, Zai Lab Limited, I-Mab Biopharma, and Janssen Biotech, Inc. Established in 2000 and headquartered in Rockville, Maryland, MacroGenics continues to make progress in the development and commercialization of antibody-based therapeutics.
MacroGenics's ticker is MGNX
The company's shares trade on the NASDAQ stock exchange
They are based in Rockville, Maryland
There are 201-500 employees working at MacroGenics
It is macrogenics.com
MacroGenics is in the Healthcare sector
MacroGenics is in the Biotechnology industry
The following five companies are MacroGenics's industry peers: